Tandem Diabetes Care (NSDQ:TNDM) yesterday touted real-world data from users of the t:slim X2 insulin pump.
The data, from more than 8,000 users, was published in the medical journal Diabetes Technology & Therapeutics.
San Diego-based Tandem said the study showed a 45% relative risk reduction in hypoglycemia and a 71% relative risk reduction in hypoglycemic events, both of which exceeded reductions observed in the controlled pivotal study for Basal-IQ technology.
Get the full story at our sister site, Drug Delivery Business News.
MassDevice Network
@MassDevice
LinkedIn
YouTube
Leave a Reply
You must be logged in to post a comment.